Trials / Completed
CompletedNCT00123201
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dronabinol MDI |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2007-03-01
- Completion
- 2007-03-01
- First posted
- 2005-07-22
- Last updated
- 2015-01-16
Locations
29 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00123201. Inclusion in this directory is not an endorsement.